

Listing of Claims**In the claims:**

1-23. (Cancelled)

24. (Currently Amended) A method for enhancing the bioavailability of a β -amyloid peptide derivative to the brain of a subject, comprising administering to the subject the β -amyloid peptide derivative and a P-glycoprotein inhibitor, wherein said P-glycoprotein inhibitor and said β -amyloid polypeptide derivative are separate chemically distinct compounds and wherein said P-glycoprotein inhibitor is not a β -amyloid peptide derivative, liposome or Tween-80, thereby enhancing the bioavailability of the β -amyloid peptide derivative to the brain of the subject.

*Okay to
enter
JR
10/21/2003*

25. (Previously Presented) The method of claim 24, wherein the β -amyloid peptide derivative is selected from the group consisting of PPI-558, PPI-657, PPI-1019, PPI-578, and PPI-655.

26. (Original) The method of claim 25, wherein the β -amyloid peptide derivative is PPI-1019.

27. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is valspodar.

28. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is cyclosporin A.

29. (Original) The method of claim 24, wherein the P-glycoprotein inhibitor is selected from the group consisting of antiarrhythmics, antibiotics, antifungals, calcium channel blockers, cancer chemotherapeutics, hormones, antiparasites, local anesthetics, phenothiazines, and tricyclic antidepressants.

30. (Original) The method of claim 24, further comprising administering to the subject a cytochrome P450 inhibitor.

31. (Original) The method of claim 24, wherein the β -amyloid peptide derivative and the P-glycoprotein inhibitor are administered simultaneously.